Search

You searched for "DMEK"

48 results found

RCOphth 2024 Preview

17 May 2024
Here is our annual highlights preview of the upcoming RCOphth 2024 Annual Congress in Belfast's ICC, 20-23 May.

Management of diabetic macular oedema (DMO)

1 February 2018 | | Retina / Uvea / Vitreous | Anti-VEGF therapy, Diabetic macular edema, Steroids
The authors present guidelines on current diagnostic and therapeutic procedures in the management of DMO. Fluorescein angiography (FA) and optical coherence tomography (OCT) are recommended before starting treatment to help diagnose and stage DMO, and can be repeated if there...
Ophthalmologica journal cover image.

Intravitreal dexamethasone in diabetic macular oedema (DMO) - enhancing the response to anti-VEGF in non- or poor responders

3 February 2023 | | Retina / Uvea / Vitreous | Aflibercept, Anti-VEGF, Dexamethasone implant, Diabetic macular oedema, Persistent, Ranibizumab, Resistant
This study aimed to describe the outcomes of a switch back from DEXi (dexamethasone implant) to anti-VEGF therapy in eyes that were treated temporarily with DEXi after an initial poor response to anti VEGF. Twenty-three eyes of 17 patients were...
Ophthalmologica journal cover image.

Ocular hypertension following intravitreal steroid injections: a comparative study between triamcinolone-acetonide and dexamethasone-implant

3 April 2023 | | Retina / Uvea / Vitreous | Dexamethasone-implant, Glaucoma, Intravitreal steroid-induced ocular hypertension, Risk factors for steroid-induced ocular hypertension, Triamcinolone-acetonide
This was a retrospective observational study of steroid response following 1549 intravitreal steroid (TA and Dex) injections. One thousand and seventy-five eyes of 897 patients were reviewed. Glaucoma patients, glaucoma suspects, uveitis, trauma, and cases with less than one month...

An eye on novel anti-cancer agents: an evidence-based approach to external eye assessment

5 April 2022 | | Ophthalmology, Cornea / External Eye Disease
Novel anti-cancer therapies have led to significant advancement in cancer treatment, however, they can be associated with external eye complications. It is important to be mindful of such adverse effects during assessment of patients enrolled in clinical trials. Annually, approximately...

Treatment of diabetic macular oedema

1 June 2014 | | Retina / Uvea / Vitreous
Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...

Management of DMO and PDR in 2019

10 October 2019 | | Ophthalmology, Retina / Uvea / Vitreous, ONLINE EXCLUSIVE ARTICLES
An evidence-based approach to the management of diabetic macular oedema (DMO) and proliferative diabetic retinopathy (PDR) in 2019 was outlined by Sobha Sivaprasad, UK, in presentations during the Diabetic Retina scientific session September 6 2019, at the 19th European Society...

Considerations in the management of retinal disorders

1 October 2017 | | Retina / Uvea / Vitreous
Vision research presentations and publications explore practice considerations in the management of AMD and diabetic retinopathy. Over the past two decades in Europe there has been a decreasing prevalence of age-related macular degeneration (AMD) and an improvement in visual acuity...

Management of retinal diseases: highlights from the AAO 2019 Retina Subspecialty Day Meeting

2 December 2019 | | Retina / Uvea / Vitreous, Ophthalmology
The author highlights current debate, opinion and late breaking developments in the management of retinal diseases. The American Academy of Ophthalmology’s 2019 Retina Subspecialty Day Meeting was held on 11-12 October, 2019 in San Francisco, USA. Established and emerging innovative...

Addressing medical risk factors for diabetes and understanding the new systemic treatments

1 February 2014 |
As global diabetes figures continue to rise, the importance of reducing the burden of macrovascular and microvascular complications of diabetes has never been so great. By 2025 it is estimated that five million people in the UK will have diabetes...

Pathophysiology of diabetic macular oedema: why combination therapy may be better

1 October 2015 | | Retina / Uvea / Vitreous
The prevalence of diabetes has continued to increase over the years. It is currently estimated that there are 382 million with diabetes worldwide in 2013, and that this figure is expected to rise to 592 million by 2035 [1]. In...

What’s next in retinal imaging? Faster, deeper and full-on

1 April 2015 | | Retina / Uvea / Vitreous, Imaging
Fast-evolving technological leaps are opening the way toward clinically useful ocular coherence angiography, generating 3-dimensional microvasculature maps without intravenous dye injection, as well as whole-eye imaging, handheld patient-operated optical coherence tomography (OCT) devices and, for challenging vitreoretinal procedures, integrated intraoperative...